|  |  | Training Sample | Validation Sample | ||||
---|---|---|---|---|---|---|---|---|
 | Healthy controls | ALS patients surviving |  | ALS patients surviving |  | |||
 |  | p-value* | < 18 months | > 18 months | p-value | < 18 months | > 18 months | p-value |
n | 69 | Â | 24 | 24 | Â | 6 | 6 | Â |
Gender (male/ female) | 34/35 | PÂ =Â 0.22 | 17/7 | 13/11 | PÂ =Â .37 | 3/3 | 2/4 | PÂ =Â 1 |
Handedness (right/left) | 64/5 | PÂ =Â .55 | 23/1 | 20/4 | PÂ =Â .35 | 5/1 | 5/1 | PÂ =Â 1 |
Age, years (means, SD**) | 59.97 (9.9) | PÂ =Â .17 | 63.18 (8) | 61.76 (10.73) | PÂ =Â .60 | 63.96 (8.03) | 55.09 (8.82) | PÂ =Â .09 |
Site of onset (bulbar/spinal) | Â | Â | 8/16 | 10/14 | PÂ =Â .76 | 3/3 | 2/4 | PÂ =Â 1 |
Diagnostic delay, years (mean, SD) | Â | Â | 1.2 (0.81) | 1.05 (0.75) | PÂ =Â .51 | 1.28 (1.1) | 0.88 (0.3) | PÂ =Â .43 |
Disease duration from symptom onset until scan, years (mean, SD) | Â | Â | 2.17 (1.01) | 2.32 (1.34) | PÂ =Â .67 | 1.94 (1.44) | 1.85 (0.54) | PÂ =Â .89 |
ALSFRS-r (mean, SD) | Â | Â | 34.48 (6.84) | 37.38 (6.21) | PÂ =Â .12 | 34.5 (8.34) | 39.17 (4.17) | PÂ =Â .25 |
King’s College Staging (1/ 2/ 3/ 4/ unavailable) |  |  | 4/5/3/7/5 | 4/9/5/4/2 |  | 0/1/2/2/1 | 2/2/1/1/0 |  |
MITOS Staging (0 /1/ 2/ 3/ unavailable) | Â | Â | 10/8/1/0/5 | 19/2/0/1/2 | Â | 3/1/1/0/1 | 6/0/0/0/0 | Â |
Survival from scan, years (mean, SD) | Â | Â | 0.94 (0.32) | 2.26 (1.11) | PÂ <Â .01 | 0.92 (0.26) | 2.62 (1.32)** | PÂ <Â .05 |